Category

• Products2

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• AMD2
• DME2
• Diabetic Retinopathy2
• Injections2
• Retina2
• Wet Amd2
• Eylea1
• Fda Approval1
• Biosimilar1
• Lawsuit1

• Organizations: Biocon Biologics✕

Clear all

Products

Settlement paves way for US commercialization of Eylea biosimilar

Biocon Biologic’s YESAFILI (aflibercept-jbvf) now expected to launch in H2 2026 after dismissal of Regeneron’s patent infringement lawsuits.

Products

FDA approves first interchangeable aflibercept biosimilars

Generic equivalents to Eylea demonstrate a comparable quality, safety, and efficacy profile for wet AMD, DME, RVO, and DR.